Haoxi Health Technology
Haoxi Health Technology's revenue rose 67.1% to $55 million in fiscal 2026. Its operating margin was −17.6%, down from −6.1% a year earlier. The diluted share count rose 2536.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What Haoxi Health Technology does
Haoxi Health Technology runs an online advertising business in China, through its Beijing operating company, Haoxi Beijing. It plans, makes, places and fine-tunes online ads, mainly short videos, for advertisers, most of them in healthcare. The ads run on large Chinese platforms such as Toutiao, Douyin, WeChat and Weibo.
It earns money by buying ad space from the platforms, or from their authorized agents, and placing ads for its clients as part of a package that includes planning and production. It uses its own data software, called Bidding Compass, to help decide where ads go. It says it has served about 2,000 advertisers since 2018; in the year to June 2026 it served 565, of which 230 were healthcare companies. Revenue that year was $54.83 million, and the company had a net loss, after profits in the two years before. It competes with other online ad agencies and with traditional media.
The listed company is a holding company outside China. In April 2025 it started a livestreaming agency service, which has not yet brought in sizeable revenue. In 2026 it signed framework agreements to explore AI-based health and marketing projects, and a non-binding letter of intent to buy an online advertising company; no final deal had been signed when it filed its report.
Its biggest risks, as it describes them
- Advertisers may cut what they spend on online marketing or stop using its services.
- Its reliance on keeping good relationships with ad platforms and their agents.
- A few customers bring in a large share of revenue, usually on contracts of a year or less.
- Unstable revenue and spending that may keep it from making a profit consistently.
- Chinese government influence over its business, and rules on moving cash out of China.
Income statement
From fiscal 2023 to 2025, earnings per share grew 6,138.1% a year and net income 97.5% a year. Haoxi Health Technology then lost money in fiscal 2026.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0 | 1 | 7 | 9 | 11 |
| Debt incl. finance leases | — | 1 | 1 | 2 | — |
| Net debt (negative means net cash) | — | −0 | −6 | −7 | — |
| Net debt to EBITDA | — | −0.3x | −3.2x | — | — |
| Debt to equity | — | 0.5x | 0.1x | 0.1x | — |
| Interest coverage | 1,304.7x | 60.5x | 41.7x | −43.5x | −184.3x |
| Current ratio | — | 1.4x | 4.0x | 5.0x | 4.5x |
| Quick ratio | — | 1.4x | 4.0x | 5.0x | 4.5x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | — | 3 of 9 | — |
| Rule of 40 | 70.2% | — | — |
| Altman Z'' | 8.56 | 9.16 | 5.28 |
| Accruals ratio | 20.4% | 39.0% | −32.3% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | — | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | — | Pass | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | — | Fail | Pass |
| F-score | — | 3 of 9 | — |
Compare
Put Haoxi Health Technology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Haoxi Health Technology | FY26 | 67.1% | −17.6% | — | — | — | — | |
| Dolphin Entertainment | FY25 | 9.7% | −0.1% | −3.6% | −0.4% | −1.0x | 4 | Compare |
| Inuvo | FY25 | 2.9% | −7.8% | −3.9% | −58.1% | — | 3 | Compare |
| Travelzoo | FY25 | 9.3% | 7.5% | 6.1% | — | −1.4x | 5 | Compare |
| IZEA Worldwide | FY25 | −12.9% | −6.0% | 7.6% | — | — | 8 | Compare |
5 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 16 | 28 | 48 | 33 | 55 |
| Revenue growth | — | 74.7% | 71.9% | −32.4% | 67.1% |
| Gross profit | 1 | 2 | 3 | 1 | 1 |
| Research and development | 0 | 0 | 0 | 0 | 0 |
| Operating income | 0 | 1 | 2 | −2 | −10 |
| Net income | 0 | 1 | 1 | 4 | −10 |
| Diluted EPS (US$) | 0.00 | 0.87 | 2,701.53 | 3,385.53 | −386.40 |
| Diluted shares (millions) | 1 | 1 | 0 | 0 | 0 |
| Cash flow | |||||
| Cash from operations | −1 | −1 | −1 | −3 | −3 |
| Capital expenditure | 0 | 0 | 0 | — | — |
| Free cash flow | −1 | −1 | −1 | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | 0 | — |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 0 | 1 | 7 | 9 | 11 |
| Debt incl. finance leases | — | 1 | 1 | 2 | — |
| Total assets | — | 4 | 16 | 22 | 22 |
| Total liabilities | — | 3 | 4 | 4 | 4 |
| Shareholders' equity | −2 | 2 | 11 | 17 | 18 |
| Margins and ratios | |||||
| Gross margin | 4.0% | 7.3% | 5.7% | 2.8% | 1.1% |
| Operating margin | 1.7% | 4.2% | 3.5% | −6.1% | −17.6% |
| Net margin | 1.5% | 3.4% | 2.7% | 11.8% | −17.4% |
| Free cash flow margin | −4.2% | −3.2% | −1.6% | — | — |
| Rule of 40 (growth + FCF margin) | — | 71.5% | 70.2% | — | — |
| Return on capital | — | — | 37.0% | −22.8% | — |
| Return on equity | — | — | 20.1% | 27.1% | −54.1% |
| Return on assets | — | — | 12.9% | 20.9% | −44.2% |
| Net debt to EBITDA | — | −0.3x | −3.2x | — | — |